Fig. 2

Flow diagram of enrollment in study and analyses. The numbers of patients who were enrolled and analyzed in this study is described. The number of excluded patients and reasons for exclusion are also described. IFN, interferon; DAA, direct-acting antiviral agent; RDI, relative dose intensity; DCV, daclatasvir; ASV, asunaprevir; SOF, sofosbuvir; RBV, ribavirin; LDV, ledipasvir; OBV, ombitasvir; PTV, paritaprevir; r, ritonavir; EBR, elbasvir; GZR, grazoprevir and SVR; sustained virological response